Literature DB >> 11750257

Phytotherapy in the management of benign prostatic hyperplasia.

F C Lowe1.   

Abstract

Phytotherapeutic agents have gained widespread usage in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. They are marketed as over-the-counter medications in the United States and by prescription in many European countries. Although numerous mechanisms of action have been postulated, it is uncertain which of these are responsible for their clinical response. The efficacy of these agents has not been conclusively proven. Almost all the studies with these products have not been placebo-controlled, double-blind trials of at least 6 months' duration. Thus, the magnitude of the clinical effect is uncertain. It is impossible to compare the phytotherapeutic agents-either the single or multiple extract products-because manufacturers use different extraction processes. So each agent/product must be studied individually. Until more appropriately conducted trials are undertaken, the efficacy of phytotherapeutic agents will remain unproven.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11750257     DOI: 10.1016/s0090-4295(01)01303-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Benign prostatic hyperplasia: an overview.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2005

2.  Quality of life in sexually active men with symptomatic benign prostatic hyperplasia : effects of treatment.

Authors:  Mel P Daly
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 3.  Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms.

Authors:  Celeste De Monte; Simone Carradori; Arianna Granese; Giovanni Battista Di Pierro; Costantino Leonardo; Cosimo De Nunzio
Journal:  BMC Urol       Date:  2014-08-11       Impact factor: 2.264

4.  Hypothesis on Serenoa repens (Bartram) small extract inhibition of prostatic 5α-reductase through an in silico approach on 5β-reductase x-ray structure.

Authors:  Paolo Governa; Daniela Giachetti; Marco Biagi; Fabrizio Manetti; Luca De Vico
Journal:  PeerJ       Date:  2016-11-22       Impact factor: 2.984

5.  Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.

Authors:  Tong Cai; Yuanshan Cui; Shaoxia Yu; Qian Li; Zhongbao Zhou; Zhenli Gao
Journal:  Am J Mens Health       Date:  2020 Mar-Apr

Review 6.  Treatment of Benign Prostatic Hyperplasia by Natural Drugs.

Authors:  Eszter Csikós; Adrienn Horváth; Kamilla Ács; Nóra Papp; Viktória Lilla Balázs; Marija Sollner Dolenc; Maša Kenda; Nina Kočevar Glavač; Milan Nagy; Michele Protti; Laura Mercolini; Györgyi Horváth; Ágnes Farkas
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

Review 7.  Phytotherapy for benign prostatic hyperplasia.

Authors:  Glenn S Gerber
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

Review 8.  Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

Authors:  M Emberton; E B Cornel; P F Bassi; R O Fourcade; J M F Gómez; R Castro
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.